微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 42.89% | -13.69% | -0.64% | 89/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 43.17% | -14.61% | -6.9% | 95/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 46.37% | -8.89% | -4.69% | 85/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 48.65% | -6.02% | -2.11% | 81/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 49.7% | 2.13% | -1.7% | 78/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 50.56% | -10.07% | -0.66% | 77/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 50.89% | -8.39% | -1.69% | 74/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 51.77% | -8.42% | 6.38% | 73/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 48.66% | -15.09% | -13.44% | 81/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 56.22% | -8.5% | 1.2% | 70/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 55.55% | -9.3% | -1.72% | 69/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 56.52% | -8.98% | -1.37% | 70/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 57.31% | -4.77% | -6.72% | 64/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 61.44% | -2.8% | 0.31% | 63/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 61.25% | -4.57% | -1.36% | 53/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 62.1% | -4.74% | 3.18% | 54/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 60.18% | -5.64% | -4.79% | 50/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 63.21% | -12.29% | -1.53% | 55/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 64.19% | -11.57% | -1.54% | 45/158 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 65.19% | -10.13% | 2.21% | 41/158 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 63.77% | -11% | -11.5% | 40/158 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 72.06% | -4.01% | -0.72% | 36/158 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 72.58% | -2.17% | 0.07% | 24/158 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 72.53% | 0.12% | 1.22% | 24/158 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 71.66% | 2.67% | -4.54% | 20/158 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 75.07% | 16.14% | 1.18% | 26/158 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 74.19% | 2% | 2.41% | 16/158 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 72.45% | 17.01% | 3.8% | 18/158 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 69.8% | 2% | 7.99% | 20/158 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 64.63% | 1.1% | 4.39% | 33/158 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 61.92% | -10% | -3.15% | 28/158 | 47.74% | 退市金泰 | 96.19% | 行业排名> |
| 2016-12-31 | 63.93% | -3.6% | -3.6% | 27/158 | 48.19% | 贝达药业 | 95.81% | 行业排名> |
| 2015-12-31 | 66.32% | -0.66% | -3.6% | 19/158 | 45.97% | 退市金泰 | 95.93% | 行业排名> |
| 2015-06-30 | 68.8% | 2% | 3.06% | 12/158 | 45% | 贝达药业 | 95.58% | 行业排名> |